JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

Benzinga · 2d ago
JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $170 to $190.